Search research articles
Contact Us
Filters
Showing results (11-20 of 63) with videos related to
Page
of 7
Sort By:
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
March 11, 2021
Efficacy and Safety of Ertugliflozin in Patients With Diabetes Mellitus Inadequately Controlled by Sulfonylurea Monotherapy: a Substudy of VERTIS CV
Krzysztof Strojek, A Shekhar Pandey, Vanessa Dell, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
February 14, 2020
SGLT2 Inhibitors and the Risk of Hospitalization for Fournier's Gangrene: A Nested Case-Control Study
Tongtong Wang, Shrita M Patel, Anne Hickman, et al.
Current Medical Research and Opinion
|
November 28, 2019
Factors associated with the discontinuation of dipeptidyl peptidase-4 inhibitors (DPP-4is) after initiation of insulin
Gail Fernandes, Joana E Matos, Dena H Jaffe, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
May 7, 2020
Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials
Shrita Patel, Anne Hickman, Robert Frederich, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
June 8, 2017
A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control
Ira Gantz, Taro Okamoto, Yuka Ito, et al.
Diabetes, Obesity & Metabolism
|
April 28, 2017
A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes
Ira Gantz, Taro Okamoto, Yuka Ito, et al.
International Journal of Clinical Practice
|
April 28, 2017
A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment
Antonio Chacra, Ira Gantz, Geraldine Mendizabal, et al.
Biochemistry
|
March 2, 2005
Receptor-antagonist interactions in the complexes of agouti and agouti-related protein with human melanocortin 1 and 4 receptors
Biao-Xin Chai, Irina D Pogozheva, Yu-Mei Lai, et al.
Cardiovascular Diabetology
|
September 13, 2017
A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus
Ira Gantz, Menghui Chen, Shailaja Suryawanshi, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 2, 2003
Peptoid mimics of agouti related protein
Darren A Thompson, Biao-Xin Chai, Hilary L E Rood, et al.
Page
of 7
Search research articles
Search
Showing results (11-20 of 63) with videos related to
Sort By:
Page
of 7
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
March 11, 2021
Efficacy and Safety of Ertugliflozin in Patients With Diabetes Mellitus Inadequately Controlled by Sulfonylurea Monotherapy: a Substudy of VERTIS CV
Krzysztof Strojek, A Shekhar Pandey, Vanessa Dell, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
February 14, 2020
SGLT2 Inhibitors and the Risk of Hospitalization for Fournier's Gangrene: A Nested Case-Control Study
Tongtong Wang, Shrita M Patel, Anne Hickman, et al.
Current Medical Research and Opinion
|
November 28, 2019
Factors associated with the discontinuation of dipeptidyl peptidase-4 inhibitors (DPP-4is) after initiation of insulin
Gail Fernandes, Joana E Matos, Dena H Jaffe, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
May 7, 2020
Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials
Shrita Patel, Anne Hickman, Robert Frederich, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
June 8, 2017
A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control
Ira Gantz, Taro Okamoto, Yuka Ito, et al.
Diabetes, Obesity & Metabolism
|
April 28, 2017
A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes
Ira Gantz, Taro Okamoto, Yuka Ito, et al.
International Journal of Clinical Practice
|
April 28, 2017
A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment
Antonio Chacra, Ira Gantz, Geraldine Mendizabal, et al.
Biochemistry
|
March 2, 2005
Receptor-antagonist interactions in the complexes of agouti and agouti-related protein with human melanocortin 1 and 4 receptors
Biao-Xin Chai, Irina D Pogozheva, Yu-Mei Lai, et al.
Cardiovascular Diabetology
|
September 13, 2017
A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus
Ira Gantz, Menghui Chen, Shailaja Suryawanshi, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 2, 2003
Peptoid mimics of agouti related protein
Darren A Thompson, Biao-Xin Chai, Hilary L E Rood, et al.
Page
of 7